ACOG

Alpha Cognition Inc. (ACOG) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This summary covers the quarterly period ended June 30, 2026. Alpha Cognition Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of treatments for neurodegenerative diseases, primarily Alzheimer's Disease. The company's core commercial product is ZUNVEYL, an oral tablet launched in March 2025. The company is classified as a Non-Accelerated Filer, Smaller Reporting Company, and Emerging Growth Company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 268% ($4.44 million) for the three months ended June 30, 2026, compared to the same period in 2025. This was driven by a 283% increase in product sales volume and a Wholesale Acquisition Cost (WAC) price increase from $749.00 to $869.36 per bottle. Licensing revenue decreased 37% due to the absence of a one-time IP transfer payment recognized in the prior year.
• Expense Increases: Operating expenses rose 36% ($3.56 million) quarter-over-quarter. Research and Development (R&D) expenses surged 395% to $2.01 million due to clinical studies and dissolvable tablet development. Selling, General, and Administrative (SG&A) expenses increased 21% to $11.45 million, primarily due to expanded sales force and marketing activities.
• Net Loss Improvement: Despite higher operating expenses, the net loss decreased 33% to $8.79 million (from $13.20 million in Q2 2025). This improvement was largely due to a significant reduction in the loss on the change in fair value of warrant liabilities, which dropped from $5.17 million in Q2 2025 to $1.41 million in Q2 2026.
• Cash Flow: Net cash used in operating activities increased to $18.66 million for the six months ended June 30, 2026, compared to $8.18 million in the prior year period, reflecting higher operational spending. Investing activities consumed $6.01 million, primarily for a $5.91 million payment to settle royalty obligations with Galantos Pharma.

Guidance, Outlook, and Risks

• Liquidity: Management believes current cash balances ($41.38 million) are sufficient to fund operations for at least the next 12 months. The company has an "At the Market" (ATM) offering agreement with H.C. Wainwright & Co. for up to $75 million, though no shares have been issued under this facility as of June 30, 2026.
• Outlook: The company expects revenue from ZUNVEYL to continue growing as it expands its sales force. Future funding requirements may be met through the ATM facility, private placements, or strategic partnerships.
• Material Weakness: The company disclosed a material weakness in internal controls over financial reporting related to the accounting of warrants, stock option liabilities, and segregation of duties. While remediation steps (additional reviews, external specialists) have been implemented, the weakness has not yet been fully remediated as of June 30, 2026.
• Accounting Revisions: The company revised prior period financial statements (2025) to reclassify Canadian Dollar (CAD) denominated options from equity to liabilities. In April 2026, these options were modified to USD, reclassifying them back to equity, eliminating future fair value volatility for these specific instruments.

Key Facts for Investor Verification

• Revenue Quality: Verify the sustainability of the 283% product sales volume increase and the impact of Gross-to-Net (GTN) deductions, which rose to 24.4% of gross sales.
• Warrant Liability Volatility: Monitor the fair value of remaining warrant liabilities ($5.08 million), as fluctuations in stock price continue to impact net loss significantly.
• Internal Controls: Track the progress of remediation efforts regarding the material weakness in financial reporting controls.
• Cash Burn Rate: Assess the runway provided by the $41.38 million cash balance against the current quarterly burn rate of approximately $15-18 million in operating cash usage.
• Intellectual Property Settlement: Confirm the long-term impact of the $5.91 million Galantos royalty settlement on future cost structures and amortization schedules.